MX2019012871A - Variantes de proteina morfogenica osea humana 7 (bmp7). - Google Patents

Variantes de proteina morfogenica osea humana 7 (bmp7).

Info

Publication number
MX2019012871A
MX2019012871A MX2019012871A MX2019012871A MX2019012871A MX 2019012871 A MX2019012871 A MX 2019012871A MX 2019012871 A MX2019012871 A MX 2019012871A MX 2019012871 A MX2019012871 A MX 2019012871A MX 2019012871 A MX2019012871 A MX 2019012871A
Authority
MX
Mexico
Prior art keywords
variants
human bmp7
bmp7 protein
protein
human
Prior art date
Application number
MX2019012871A
Other languages
English (en)
Inventor
Louis Frank Stancato
James David Pancook
Scott William Rowlinson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2019012871A publication Critical patent/MX2019012871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2857—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, orphan receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a variantes novedosas de la proteína BMP7 humana. La invención incorpora vectores y células hospederas para la propagación de secuencias de ácido nucleico que codifican las proteínas y la producción de las mismas. También se describen métodos para el tratamiento de cáncer, daño y degeneración de cartílago, dolor asociado con osteoartritis, o curación ósea.
MX2019012871A 2017-04-27 2018-04-20 Variantes de proteina morfogenica osea humana 7 (bmp7). MX2019012871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762490910P 2017-04-27 2017-04-27
PCT/US2018/028496 WO2018200322A1 (en) 2017-04-27 2018-04-20 Variants of human bmp7 protein

Publications (1)

Publication Number Publication Date
MX2019012871A true MX2019012871A (es) 2021-01-08

Family

ID=62196685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012871A MX2019012871A (es) 2017-04-27 2018-04-20 Variantes de proteina morfogenica osea humana 7 (bmp7).

Country Status (17)

Country Link
US (1) US11466066B2 (es)
EP (1) EP3615561B1 (es)
JP (1) JP7308151B2 (es)
KR (1) KR20200012870A (es)
CN (1) CN110997708A (es)
AU (1) AU2018258100B2 (es)
BR (1) BR112019022566A2 (es)
CA (1) CA3061606A1 (es)
CL (1) CL2019003074A1 (es)
CO (1) CO2019013150A2 (es)
CR (1) CR20190539A (es)
EA (1) EA201992558A1 (es)
MX (1) MX2019012871A (es)
PE (1) PE20200385A1 (es)
PH (1) PH12019502442A1 (es)
SG (1) SG11201910009UA (es)
WO (1) WO2018200322A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101885737B1 (ko) 2018-04-30 2018-08-06 주식회사 이지요구르트 요구르트발효기 및 요구르트발효기의 자동 온도제어 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500816A (ja) 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
AU2007339280B2 (en) 2006-12-21 2013-12-05 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
JP2010531135A (ja) 2007-06-04 2010-09-24 ノボ ノルディスク アクティーゼルスカブ Ｎ−アセチルグルコサミニルトランスフェラーゼを使用したｏ結合型グリコシル化
US7846428B2 (en) 2007-10-05 2010-12-07 Merial Limited Articular cartilage gene therapy with recombinant vector encoding BMP-7
US20110039773A1 (en) 2007-12-21 2011-02-17 Stryker Biotech BMP Mutants with Decreased Susceptibility to Noggin

Also Published As

Publication number Publication date
EP3615561B1 (en) 2024-01-10
KR20200012870A (ko) 2020-02-05
EA201992558A1 (ru) 2020-03-04
BR112019022566A2 (pt) 2020-05-19
CO2019013150A2 (es) 2020-02-28
US11466066B2 (en) 2022-10-11
AU2018258100B2 (en) 2022-04-14
EP3615561C0 (en) 2024-01-10
AU2018258100A1 (en) 2019-11-14
WO2018200322A1 (en) 2018-11-01
JP7308151B2 (ja) 2023-07-13
CA3061606A1 (en) 2018-11-01
CN110997708A (zh) 2020-04-10
PE20200385A1 (es) 2020-02-24
PH12019502442A1 (en) 2020-10-05
US20210115100A1 (en) 2021-04-22
CL2019003074A1 (es) 2020-05-08
SG11201910009UA (en) 2019-11-28
CR20190539A (es) 2020-03-26
JP2020517706A (ja) 2020-06-18
EP3615561A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
MX2018001040A (es) Moleculas de acido nucleico artificiales.
CR20220136A (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
MX2020009514A (es) Anticuerpos anti-claudina 18.2 (cldn18.2).
WO2017077329A3 (en) Nucleic acids, peptides and methods
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
TW201613954A (en) Interleukin-10 fusion proteins and uses thereof
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
MY185845A (en) Icos binding proteins
PH12020551907A1 (en) Antagonizing cd73 antibody
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
PH12019500571A1 (en) Anti-pd-1 antibodies
WO2014111458A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
CR20220076A (es) Anticuerpos anti-cd96 y sus métodos de uso
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof